Skip to main content Accessibility help
  • Print publication year: 2009
  • Online publication date: June 2012

10 - Technologies for early detection and prevention of cancer

,American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society; 2007.
Miniño, AM, Heron, MP, Smith, BL. Deaths: Preliminary Data for 2004. National Vital Statistics Report. 2006 June 28;54(19).
,American Cancer Society. Cancer Facts and Figures 2005. Atlanta: American Cancer Society; 2005.
Edwards, BK, Brown, ML, Wingo, PA, Howe, HL, Ward, E, Ries, LAG, et al. Annual Report to the Nation on the Status of Cancer, 1975–2002, Featuring Population-Based Trends in Cancer Treatment. Journal of the National Cancer Institute. 2005 October 5; 97(19).
,WHO. Mortality: Revised Global Burden of Disease (2002) Estimates. Geneva: World Health Organization; 2002.
Parkin, DM, Bray, F, Ferlay, J, Pisani, P. Global cancer statistics, 2002. CA: a Cancer Journal for Clinicians. 2005 Mar–Apr; 55(2): 74–108.
,International Union Against Cancer. Global Action Against Cancer. Geneva: WHO/UICC; 2005.
,World Health Organization. Global Cancer Rates Could Increase by 50% to 15 Million by 2020. Geneva: World Health Organization; 2003 April 3.
,American Cancer Society. The Case for Global Action. 2007 [cited 2007 May 9]; Available from:
,American Cancer Society. Lifetime Probability of Developing or Dying from Cancer. 2006 February 22 [cited 2007 May 9]; Available from: 6x_Lifetime_Probability_of_Developing_or_Dying_From_Cancer.asp?sitearea=
Stewart, BW, Kleihues, P, eds. World Cancer Report. Lyon: IARC Press; 2003.
,American Cancer Society. Cancer Statistics 2005 [PowerPoint]. Atlanta: American Cancer Society; 2005.
MacKay, J, Eriksen, M. The Tobacco Atlas. Geneva: The World Health Organization; 2002.
,American Cancer Society. Cancer Prevention and Early Detection Facts and Figures 2007. Atlanta: American Cancer Society; 2007.
Hanahan, D, Weinberg, RA. The hallmarks of cancer. Cell. 2000 Jan 7; 100(1): 57–70.
,Dolan DNA Learning Center – Cold Spring Harbor Laboratory. Inside Cancer. [Multimedia Guide] 2004 [cited 2007 May 10]; Available from:
Cotran, RS, Kumar, V, Robbins, SL. Robbins Pathologic Basis of Disease. 5th edn. W.B. Saunders Company; 1994.
,National Cancer Institute. Milestone (1971): President Nixon declares war on cancer. 2007 [cited 2007 May 10]; Available from:
Niederhuber, JE. The Nation's Investment in Cancer Research. Frederick, Maryland: National Cancer Institute; 2006 October.
,National Cancer Institute. The NCI Strategic Plan for Leading the Nation. Frederick, Maryland: National Cancer Institute; 2006 January.
,National Center for Health Statistics. Health, United States, 2006 With Chartbook on Trends in the Health of Americans. Hyattsville, MD; 2006.
Carr, DB, Loeser, JD, Morris, DB. Narrative, Pain and Suffering (Progress in Pain Research and Management). Seattle, WA: IASP Press; 2005.
Wang, XS, Li, TD, Yu, SY, Gu, WP, Xu, GW. China: status of pain and palliative care. Journal of Pain and Symptom Management. 2002 Aug; 24(2): 177–9.
,US Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd edn. Alexandria, VA: International Medical Publishing; 1996.
Elmore, JG, Armstrong, K, Lehman, CD, Fletcher, SW. Screening for breast cancer. Jama. 2005 Mar 9; 293(10): 1245–56.
Warner, E, Plewes, DB, Hill, KA, Causer, PA, Zubovits, JT, Jong, RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. Jama. 2004 Sep 15; 292(11): 1317–25.
Thomas, DB, Gao, DL, Ray, RM, Wang, WW, Allison, CJ, Chen, FL, et al. Randomized trial of breast self-examination in Shanghai: final results. Journal of the National Cancer Institute. 2002 Oct 2;94(19): 1445–57.
,American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.
Humphrey, LL, Helfand, M, Chan, BK, Woolf, SH. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. Annals of Internal Medicine. 2002 Sep 3; 137(5 Part 1): 347–60.
Parkin, DM, Bray, F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006 Aug 21; 24 Suppl. 3: S11–25.
Nijhuis, ER, Reesink-Peters, N, Wisman, GB, Nijman, HW, Zanden, J, Volders, H, et al. An overview of innovative techniques to improve cervical cancer screening. Cell Oncology. 2006; 28(5–6): 233–46.
Burchell, AN, Richardson, H, Mahmud, SM, Trottier, H, Tellier, PP, Hanley, J, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. American Journal of Epidemiology. 2006 Mar 15; 163(6): 534–43.
,American Cancer Society. FDA Approves New Cervical Cancer Screening Test. 2003 March 31 [cited 2007 May 10]; Available from:
Cohen, J. Public health. High hopes and dilemmas for a cervical cancer vaccine. Science (New York, NY). 2005 Apr 29; 308(5722): 618–21.
Alberts, B. Molecular Biology of the Cell. 3rd edn. New York: Garland Publishing; 1994.
Renshaw, AA. Measuring sensitivity in gynecologic cytology: a review. Cancer. 2002 Aug 25; 96(4): 210–17.
,Centers for Disease Control. Regulations for Implementing the Clinical Laboratory Improvement Amendments of 1988: a Summary. MMWR. 1992 (No. RR-2).
Austin, RM. Human papillomavirus reporting: minimizing patient and laboratory risk. Archives of Pathology & Laboratory Medicine. 2003 Aug; 127(8): 973–7.
Bogdanich, W. Lax Laboratories: The Pap Test misses much cervical cancer through lab's errors. The Wall Street Journal. 1987 November 2.
Nanda, K, McCrory, DC, Myers, ER, Bastian, , Hasselblad, V, Hickey, JD, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Annals of Internal Medicine. 2000 May 16; 132(10): 810–19.
Fahey, MT, Irwig, L, Macaskill, P. Meta-analysis of Pap test accuracy. American Journal of Epidemiology. 1995 Apr 1; 141(7): 680–9.
Mitchell, MF, Schottenfeld, D, Tortolero-Luna, G, Cantor, SB, Richards-Kortum, R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstetrics and Gynecology. 1998 Apr; 91(4): 626–31.
Welch, HG. Should I be Tested for Cancer?Berkely, CA: University of California Press; 2004.
Ferenczy, A, Franco, E. Cervical-cancer screening beyond the year 2000. The Lancet Oncology. 2001 Jan; 2(1): 27–32.
Hutchinson, ML. Assessing the costs and benefits of alternative rescreening strategies. Acta Cytologica. 1996 Jan–Feb; 40(1): 4–8.
Kurman, RJ, Henson, , Herbst, AL, Noller, KL, Schiffman, MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. Jama. 1994 Jun 15; 271(23): 1866–9.
Jeronimo, J, Morales, O, Horna, J, Pariona, J, Manrique, J, Rubinos, J, et al. Visual inspection with acetic acid for cervical cancer screening outside of low-resource settings. Revista Panamericana de Salud Publica (Pan American Journal of Public Health). 2005 Jan; 17(1): 1–5.
Birdsong, GG. Automated screening of cervical cytology specimens. Human Pathology. 1996 May; 27(5): 468–81.
Groopman, J. Contagion: Papilloma Virus. The New Yorker. 1999 September 13.
Saslow, D, Runowicz, CD, Solomon, D, Moscicki, AB, Smith, RA, Eyre, HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA: a Cancer Journal for Clinicians. 2002 Nov–Dec; 52(6): 342–62.
Russell, J, Crothers, BA, Kaplan, KJ, Zahn, CM. Current cervical screening technology considerations: liquid-based cytology and automated screening. Clinical Obstetrics and Gynecology. 2005 Mar; 48(1): 108–19.
,Health Technologies Advisory Committee – Minnesota. New technologies for cervical cancer screening: strategies to lower the rate of cervical cancer. Health Services/Technology Assessment Text (HSTAT). National Library of Medicine; 1999.
,FDA. FDA Approves Expanded Use of HPV Test. 2003 March 31 [cited 2007 May 20]; Available from:
Schiffman, M, Herrero, R, Hildesheim, A, Sherman, ME, Bratti, M, Wacholder, S, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. Jama. 2000 Jan 5; 283(1): 87–93.
Arbyn, M, Sasieni, P, Meijer, CJ, Clavel, C, Koliopoulos, G, Dillner, J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006 Aug 21; 24 Suppl. 3: S78–89.
,Digene Corporation. Hybrid Capture® 2 High-Risk HPV DNA TestTM [cited 2007 May 20]; Product Insert]. Available from:,%20hc2%20HPV%20DNA%20Test%20US.pdf
Germar, MJ, Marialdi, M. Visual inspection with acetic acid as a cervical cancer screening tool for developing countries. Review for the 12th Postgraduate Training Course in Reproductive Health/Chronic Disease 2003 [cited 2007 May 28]; Available from: http://www. cancer.htm
,Coalition NCC. NCCC Section on the HPV Vaccine. 2007 [cited 2007 March 2]; Available from:
Cohen, J. High hopes and dilemmas for a cervical cancer vaccine. Science (New York, NY). 2003; 308: 618–21.
Kane, MA, Sherris, J, Coursaget, P, Aguado, T, Cutts, F. Chapter 15: HPV vaccine use in the developing world. Vaccine. 2006 Aug 21; 24 Suppl. 3: S132–9.
Sankaranarayanan, R, Shastri, SS, Basu, P, Mahe, C, Mandal, R, Amin, G, et al. The role of low-level magnification in visual inspection with acetic acid for the early detection of cervical neoplasia. Cancer Detection and Prevention. 2004; 28(5): 345–51.
,Pan American Health Organization. Visual Inspection of the Uterine Cervix with Acetic Acid (VIA): A Critical Review and Selected Articles. Washington, D.C.; 2003.
Park, SY, Follen, M, Milbourne, A, Rhodes, H, Malpica, A, MacKinnon, M, et al. Automated image analysis of digital colposcopy for the detection of cervical neoplasia. Manuscript submitted for publication, 2007.
Kasper, D, Braunwald, E, Fauci, A, Longo, D, Hauser, S, Jameson, JL, eds. Harrison's Principles of Internal Medicine. 16th edn. New York City: McGraw-Hill; 2005.
Hutchinson, K, Wener, M. National Health and Nutrition Examination Survey Lab Methods 2003–2004: Total Prostate-Specific Antigen (PSA). University of Washington Medical Center; 2007 May 4.
,Aureon Biosystems. LumiPhos Plus. [cited 2007 March 10]; Available from:
,Lumigen. Lumigen PPD. 2006 [cited 2007 March 10]; Available from:
Hernandez, J, Thompson, IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004 Sep 1; 101(5): 894–904.
Albertsen, PC. Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?Acta Oncologica (Stockholm, Sweden). 2005; 44(3): 255–64.
Gottlieb, RH, Mooney, C, Mushlin, AI, Rubens, DJ, Fultz, PJ. The prostate: decreasing cost-effectiveness of biopsy with advancing age. Investigative Radiology. 1996 Feb; 31(2): 84–90.
,American Cancer Society. How Is Prostate Cancer Diagnosed? 2006 July 26 [cited 2007 May 20]; Available from:
Lu-Yao, GL, Yao, SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. The Lancet. 1997 Mar 29; 349(9056): 906–10.
Neal, , Leung, HY, Powell, PH, Hamdy, FC, Donovan, JL. Unanswered questions in screening for prostate cancer. European Journal of Cancer. 2000 Jun; 36(10): 1316–21.
Bartsch, G, Horninger, W, Klocker, H, Reissigl, A, Oberaigner, W, Schonitzer, D, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001 Sep; 58(3): 417–24.
Horninger, W, Berger, A, Pelzer, A, Klocker, H, Oberaigner, W, Schonitzer, D, et al. Screening for prostate cancer: updated experience from the Tyrol study. The Canadian Journal of Urology. 2005 Feb; 12 Suppl. 1: 7–13; discussion 92–3.
Ilic, D, O'Connor, D, Green, S, Wilt, T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control. 2007 Apr; 18(3): 279–85.
Amling, CL. Prostate-specific antigen and detection of prostate cancer: what have we learned and what should we recommend for screening?Current Treatment Options in Oncology. 2006 Sep; 7(5): 337–45.
Hennekens, CH, Buring, JE. Epidemiology In Medicine. Philadelphia: Lippincott Williams & Wilkins; 1987.
Welch, HG, Schwartz, LM, Woloshin, S. Are increasing 5-year survival rates evidence of success against cancer?Jama. 2000 Jun 14; 283(22): 2975–8.
Reynolds, EA, Moller, KA. A review and an update on the screening of epithelial ovarian cancer. Current Problems in Cancer. 2006 Sep–Oct; 30(5): 203–32.
Rosenthal, AN, Menon, U, Jacobs, IJ. Screening for ovarian cancer. Clinical Obstetrics and Gynecology. 2006 Sep; 49(3): 433–47.
,BC Cancer Agency. Years of Life Lost. 2005 July 25 [cited 2007 May 22]; Available from:
Petricoin, EF, Ardekani, AM, Hitt, BA, Levine, PJ, Fusaro, VA, Steinberg, SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. The Lancet. 2002 Feb 16; 359(9306): 572–7.
Urban, N. Specific keynote: ovarian cancer risk assessment and the potential for early detection. Gynecologic Oncology. 2003 Jan; 88(1 Pt 2): S75–9; discussion S80–3.
Nahhas, WA. Ovarian cancer. Current outlook on this deadly disease. Postgraduate Medicine. 1997 Sep; 102(3): 112–20.
Zurawski, VR, Jr., Sjovall, K, Schoenfeld, DA, Broderick, SF, Hall, P, Bast, RC, Jr., et al. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecologic Oncology. 1990 Mar; 36(3): 299–305.
Gladstone, CQ. Screening for ovarian cancer. In: ,Canadian Task Force on Periodic Health Examination, ed. Canadian Guide to Clinical Preventive Health Care. Ottawa: Health Canada; 1994: 870–81.
Menon, U, Jacobs, IJ. Ovarian cancer screening in the general population. Current Opinion in Obstetrics & Gynecology. 2001 Feb; 13(1): 61–4.
Nagell, JR, DePriest, PD, Reedy, MB, Gallion, HH, Ueland, FR, Pavlik, EJ, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecologic Oncology. 2000 Jun; 77(3): 350–6.
Lok, IH, Sahota, DS, Rogers, MS, Yuen, PM. Complications of laparoscopic surgery for benign ovarian cysts. The Journal of the American Association of Gynecologic Laparoscopists. 2000 Nov; 7(4): 529–34.
Hensley, ML, Spriggs, . Cancer screening: how good is good enough? Journal of Clinical Oncology. 2004 Oct 15; 22(20): 4037–9.
Johnson, D, Sandmire, D, Klein, D. Ovarian Cancer. In Medical Tests That Can Save Your Life: 21 Tests Your Doctor Won't Order Unless You Know to Ask. Emmaus, PA Rodale; 2004.
Fees Involved in Infertility Treatments. 2005 [cited 2007 June 1]; Available from:
Jacobs, IJ, Skates, S, Davies, AP, Woolas, RP, Jeyerajah, A, Weidemann, P, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ (Clinical Research Ed.) 1996 Nov 30; 313(7069): 1355–8.
Jacobs, IJ, Skates, SJ, MacDonald, N, Menon, U, Rosenthal, AN, Davies, AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. The Lancet. 1999 Apr 10; 353(9160): 1207–10.
UK Collaborative Trial of Ovarian Cancer Screening. 2006 July 11 [cited 2007 May 20]; Available from:
Buys, SS, Partridge, E, Greene, MH, Prorok, PC, Reding, D, Riley, TL, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. American Journal of Obstetrics and Gynecology. 2005 Nov; 193(5): 1630–9.
,FDA. Protein Patterns May Identify Ovarian Cancer. 2002 February 7 [cited 2007 May 20]; Available from:
Pollack, A. New cancer test stirs hope and concern. The New York Times. 2004 February 3.
Underwood, A. Testing: ovarian cancer. Newsweek. 2002 February 18: 12.
Baggerly, KA, Morris, JS, Coombes, KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics (Oxford, England). 2004 Mar 22; 20(5): 777–85.
,American Cancer Society, How Many People Get Lung Cancer, 2004; Available from: